Hematologia
Revisão | Diagnóstico e tratamento de síndromes mielodisplásicas.
8 Set, 2022 | 14:17hDiagnosis and Treatment of Myelodysplastic Syndromes: A Review – JAMA (gratuito por tempo limitado)
Revisão clínica em áudio: Diagnosis and Management of Myelodysplastic Syndromes – JAMA
Estudo de coorte | Determinantes clínicos e moleculares da evolução clonal na anemia aplástica e na hemoglobinúria noturna paroxística.
8 Set, 2022 | 14:09hClinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)
Comentário do autor no Twitter (fio – clique para saber mais)
Super excited to share our multicenter study on clonal evolution in 1008 patients with AA/PNH followed for a median f-up of 9 yrs now out in @JCO_ASCO https://t.co/j9U2ZjYX0o
— Carmelo Gurnari (@CarmeloGurnari) September 2, 2022
Breve revisão | Tromboprofilaxia na terapia intensiva.
8 Set, 2022 | 14:06hThromboprophylaxis in critical care – Intensive Care Medicine
Revisão | Uso de transfusão de sangue total no trauma.
8 Set, 2022 | 13:34hThe Use of Whole Blood Transfusion in Trauma – Current Anesthesiology Reports
Revisão sistemática | Hidroxiureia para doença falciforme.
6 Set, 2022 | 12:42hHydroxyurea (hydroxycarbamide) for sickle cell disease – Cochrane Library
Resumo: Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease – Cochrane Library
Estudo de braço único fase 2 | Rituximabe, lenalidomida e ibrutinibe em pacientes com linfoma de grandes células B recém-diagnosticado.
29 Ago, 2022 | 17:30hSmart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
In a phase II study in 60 pts with newly diagnosed DLBCL, the ORR after 2 cycles of rituximab, lenalidomide & ibrutinib was 86.2%, with a CR rate of 94.5% after a further 6 cycles together with standard chemo; 2-yr PFS & OS were 91.3% & 96.6%, respectively https://t.co/lvNs8DFSYp
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
Resultados de longo prazo de um estudo randomizado | Lenalidomida com rituximabe vs. rituximabe em quimioterapia seguida de rituximabe de manutenção no linfoma folicular avançado não tratado.
29 Ago, 2022 | 17:27hComentários:
Comentário no Twitter
6-year update from the phase III RELEVANCE trial of lenalidomide-rituximab versus rituximab-chemotherapy in previously untreated patients with advanced-stage follicular lymphoma demonstrates very similar durable efficacy and safety: https://t.co/rMeA2tOoO6 #lymsm #hemeonc
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
Revisão | Reações à transfusão sanguínea.
29 Ago, 2022 | 13:38h
Estudo de braço único fase 2 | Segurança e eficácia do mitapivate, ativador oral da piruvatequinase, em adultos com alfatalassemia ou betatalassemia não dependente de transfusão.
22 Ago, 2022 | 16:28hSafety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study – The Lancet (link para o resumo – $ para o texto completo)
Comentário: PK Modulator Shows Promise in Thalassemia — In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients – MedPage Today (necessário cadastro gratuito)
Diretriz | Uso de plasma convalescente de COVID-19.
22 Ago, 2022 | 16:08hComunicado de imprensa: The AABB releases clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma – American College of Physicians